hydroxyurea has been researched along with Pregnancy in 206 studies
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to investigate the effect of astilbin on pregnancy outcome in rats with recurrent spontaneous abortion (RSA)." | 8.12 | Astilbin improves pregnancy outcome in rats with recurrent spontaneous abortion by regulating Th1/Th2 balance. ( Jiang, W; Pei, Y; Qian, Y; Zheng, C, 2022) |
| "What is the prevalence and incidence of congenital anomalies among babies born to women with sickle cell disease (SCD) and who have been exposed to hydroxyurea (HU) therapy at any time in their pregnancy?The objective of this review is to identify the proportion of babies born with congenital anomalies among babies born to mothers with SCD who have been exposed to HU therapy at any point during pregnancy and to describe the specific types of congenital anomalies encountered." | 7.88 | Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol. ( Gwer, SO; Onyango, KO, 2018) |
| "The aim of this study was to evaluate the efficacy and toxicity profile of the cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine (CHAMOC) regimen in the treatment of high-risk gestational trophoblastic neoplasia (GTN)." | 7.81 | Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia. ( Chan, KK; Chu, MM; Ma, Y; Ngan, HY; Tse, KY, 2015) |
| " Various doses of hydroxyurea, a teratogen to the rodent central nervous system, were administered to curly-tail mice on either day 8 or day 9 of pregnancy in an attempt to increase the number of NTD in the embryos." | 7.66 | Effect of hydroxyurea on neural tube defects in the curly-tail mouse. ( Perkins, KJ; Seller, MJ, 1983) |
| " Combined with animal data, research using these approaches might be able to define safe and effective hydroxyurea dosing regimens for pregnant and lactating women with SCA, when the benefits of continuing hydroxyurea treatment likely outweigh the risks of non-treatment, by avoiding substantial morbidity and even mortality for both mothers and infants." | 7.01 | Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. ( Dallmann, A; Dong, M; Vinks, AA; Ware, RE, 2023) |
| "The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) was a randomized double-blind placebo-controlled trial to test whether hydroxyurea could reduce the rate of painful crises in adults who had at least 3 painful crises per year." | 6.74 | Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. ( Ballas, SK; Barton, BA; Bellevue, R; DeCastro, L; Guo, N; McCarthy, WF; Waclawiw, MA, 2009) |
| "The use of hydroxyurea in chronic myeloid leukemia during pregnancy is unknown." | 6.67 | Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report. ( Dukes, IA; Hull, JC; Patel, M, 1991) |
| "A patient being treated for sickle cell disease with hydroxyurea (1 g/d) conceived, and drug treatment was discontinued at nine weeks gestational age." | 6.40 | Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature. ( Diav-Citrin, O; Hunnisett, L; Koren, G; Sher, GD, 1999) |
| " Contraception is strongly recommended while on hydroxyurea therapy during reproductive years and discontinuing hydroxyurea for family planning and during pregnancy based on teratogenicity in animal studies." | 4.95 | Fertility challenges for women with sickle cell disease. ( Day, ME; DeBaun, MR; Ghafuri, DL; James, A; Sharma, D; Stimpson, SJ, 2017) |
| " Pregnancy is a high-risk situation for the mother and child The efficacy and safety of hydroxyurea and long-term blood transfusions in adults with sickle cell disease are currently under investigation." | 4.84 | [New issues in adult sickle sell disease]. ( Girot, R; Lionnet, F; Stankovic, K, 2008) |
| " Results of the first phase III trial (PT1) that compared anagrelide/aspirin with hydroxyurea/aspirin have sparked an intense discussion, given that the combination of anagrelide and aspirin causes more bleeding complications in the gastrointestinal tract." | 4.83 | Anagrelide: what was new in 2004 and 2005? ( Petrides, PE, 2006) |
| "The purpose of this study was to investigate the effect of astilbin on pregnancy outcome in rats with recurrent spontaneous abortion (RSA)." | 4.12 | Astilbin improves pregnancy outcome in rats with recurrent spontaneous abortion by regulating Th1/Th2 balance. ( Jiang, W; Pei, Y; Qian, Y; Zheng, C, 2022) |
| "Chemotherapeutic agents such as methotrexate (MTX), raltitrexed (RTX), 5-fluorouracil (5-FU), hydroxyurea (HU), and retinoic acid (RA), and valproic acid (VPA), an antiepileptic drug, all can cause malformations in the developing central nervous system (CNS), such as neural tube defects (NTDs)." | 4.12 | Unraveling the Mechanisms of Clinical Drugs-Induced Neural Tube Defects Based on Network Pharmacology and Molecular Docking Analysis. ( Guan, Z; Li, S; Liang, Y; Niu, B; Wang, J; Wang, X; Yang, A; Yu, J; Zhu, Z, 2022) |
| "What is the prevalence and incidence of congenital anomalies among babies born to women with sickle cell disease (SCD) and who have been exposed to hydroxyurea (HU) therapy at any time in their pregnancy?The objective of this review is to identify the proportion of babies born with congenital anomalies among babies born to mothers with SCD who have been exposed to HU therapy at any point during pregnancy and to describe the specific types of congenital anomalies encountered." | 3.88 | Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol. ( Gwer, SO; Onyango, KO, 2018) |
| "The aim of this study was to evaluate the efficacy and toxicity profile of the cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine (CHAMOC) regimen in the treatment of high-risk gestational trophoblastic neoplasia (GTN)." | 3.81 | Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia. ( Chan, KK; Chu, MM; Ma, Y; Ngan, HY; Tse, KY, 2015) |
| "Exposure to hydroxyurea caused a dose-dependent increase in fetal deaths that was not affected by hSOD1 expression; hydroxyurea decreased fetal weights in litters from wild-type but not hemizygous dams." | 3.75 | The impact of human superoxide dismutase 1 expression in a mouse model on the embryotoxicity of hydroxyurea. ( Hales, BF; Larouche, G, 2009) |
| "Hydroxyurea is classified as an S-phase antineoplastic agent (pregnancy category D)." | 3.70 | Hydroxyurea in two pregnant women with sickle cell anemia. ( Alexander, CK; Byrd, DC; Pitts, SR, 1999) |
| "Hydroxyurea was stopped for medical reasons in 11 patients: 6 failures, 1 pregnancy, 1 cutaneous rash, 1 leg ulcer, 1 lupus." | 3.70 | Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. ( Bachir, D; Bégué, P; Bernaudin, F; de Montalembert, M; Micheau, M; Thuret, I, 1999) |
| " A care of pregnancy complicated by essential thrombocythemia treated with aspirin, antiaggregating agent, throughout pregnancy and with hydroxyurea, a platelet lowering drug is reported." | 3.69 | [Essential thrombocythemia in pregnancy. A case report and general considerations]. ( Catalano, D; Dell'Isola, A; Di Rosa, G, 1997) |
| "The authors report about a successful labour and delivery after pregnancy with chronic myeloid leukemia treated with hydroxyurea." | 3.68 | [Successful delivery following continuous cytostatic therapy of a leukemic pregnant women]. ( Kovács, L; Szántó, F, 1993) |
| "On day 10 of pregnancy NMRI mice received an intraperitoneal injection of either 500 mg/kg hydroxyurea (HU) or 500 mg/kg HU plus 500, 700, 800, or 900 mg/kg deoxycytidine monophosphate (dCMP)." | 3.67 | The influence of deoxycytidine monophosphate (dCMP) on the cytotoxicity of hydroxyurea in the embryonic spinal cord of the mouse. ( Herken, R, 1984) |
| " It has been found that maternal administration of hydroxyurea, mitomycin C, or 5-fluorouracil on day 9 of pregnancy, that is, when the fetal neural tube is in the final stages of closure, leads to a significant reduction in the proportion of NTD (to 15 to 20%) in the offspring, while total litter size is unaffected." | 3.66 | The cause of neural tube defects: some experiments and a hypothesis. ( Seller, MJ, 1983) |
| "Treatment of choriocarcinoma cells (JAr line) for 24 hr with methotrexate, fluorodeoxyuridine, 1-beta-D-arabinofuranosylcytosine, or hydroxyurea, in doses that inhibit DNA synthesis, results in a 2." | 3.66 | Stimulation of human chorionic gonadotropin by JAr line choriocarcinoma after inhibition of DNA synthesis. ( Azizkhan, JC; Goode, D; Speeg, KV; Stromberg, K, 1979) |
| " Various doses of hydroxyurea, a teratogen to the rodent central nervous system, were administered to curly-tail mice on either day 8 or day 9 of pregnancy in an attempt to increase the number of NTD in the embryos." | 3.66 | Effect of hydroxyurea on neural tube defects in the curly-tail mouse. ( Perkins, KJ; Seller, MJ, 1983) |
| "Rats whose mothers received hydroxyurea (HU, 1 or 2 g/kg) at 14 days of gestation had a 30% deficit in both brain and body weight at birth, when compared with controls." | 3.65 | Maze learning by adult rats after inhibition of neuronal multiplication in utero. ( Adlard, BP; Dobbing, J, 1975) |
| " Combined with animal data, research using these approaches might be able to define safe and effective hydroxyurea dosing regimens for pregnant and lactating women with SCA, when the benefits of continuing hydroxyurea treatment likely outweigh the risks of non-treatment, by avoiding substantial morbidity and even mortality for both mothers and infants." | 3.01 | Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. ( Dallmann, A; Dong, M; Vinks, AA; Ware, RE, 2023) |
| "The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) was a randomized double-blind placebo-controlled trial to test whether hydroxyurea could reduce the rate of painful crises in adults who had at least 3 painful crises per year." | 2.74 | Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. ( Ballas, SK; Barton, BA; Bellevue, R; DeCastro, L; Guo, N; McCarthy, WF; Waclawiw, MA, 2009) |
| "The use of hydroxyurea in chronic myeloid leukemia during pregnancy is unknown." | 2.67 | Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report. ( Dukes, IA; Hull, JC; Patel, M, 1991) |
| "In women with Stage IIIB cervical cancer there was a trend toward longer survival in those receiving hydroxyurea (52." | 2.64 | Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. ( Barlow, JJ; Blumenson, L; Piver, MS; Vongtama, V, 1977) |
| " Several studies have indicated that HU is well tolerated and safe in pregnant women and very young pediatric patients." | 2.58 | An Animal Model for Assessing the Effects of Hydroxyurea Exposure Suggests That the Administration of This Agent to Pregnant Women and Young Infants May Not Be as Safe as We Thought. ( Martí, J; Rodríguez-Vázquez, L, 2018) |
| "Sickle cell disease is a common and life-threatening haematological disorder that affects millions of people worldwide." | 2.55 | Sickle cell disease. ( Abboud, MR; de Montalembert, M; Tshilolo, L; Ware, RE, 2017) |
| "Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage." | 2.49 | [Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013) |
| "Hydroxyurea has proven clinical efficacy for reducing acute vaso-occlusive events including pain episodes and acute chest syndrome." | 2.45 | Advances in the use of hydroxyurea. ( Aygun, B; Ware, RE, 2009) |
| "Primary thrombocythemia is a rare acquired chronic disorder of the bone marrow which can occur at any age." | 2.43 | [Primary thrombocythemia: diagnosis and therapy]. ( Petrides, PE, 2006) |
| "A patient being treated for sickle cell disease with hydroxyurea (1 g/d) conceived, and drug treatment was discontinued at nine weeks gestational age." | 2.40 | Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature. ( Diav-Citrin, O; Hunnisett, L; Koren, G; Sher, GD, 1999) |
| "Essential thrombocythemia is a chronic myeloproliferative disease characterized by persistent thrombocytosis and an increased risk of thromboembolic complications." | 2.40 | [A management program for primary thrombocytopenia]. ( Bruserud, O; Knutsen, H, 1999) |
| " Guidelines regarding patient selection, dosing schedules, treatment goals, and short- and long-term monitoring parameters need to be established." | 2.40 | Use of hydroxyurea in children with sickle cell disease: what comes next? ( Ohene-Frempong, K; Smith-Whitley, K, 1997) |
| "Aspirin (ASS) was the most frequently used drug in 47 of 93 recorded cases (51%)." | 2.39 | Essential thrombocythemia and pregnancy. ( Griesshammer, M; Heimpel, H; Pearson, TC, 1996) |
| " Pups were dosed with the same dose as their respective dam starting on postnatal day (PND) 10 and up to PND 34." | 1.62 | Tolerability and age-dependent toxicokinetics following perinatal hydroxyurea treatment in Sprague Dawley rats. ( Black, SR; Fennell, TR; Fernando, RA; Huang, MC; Lu, Y; McIntyre, BS; Price, CJ; Robinson, VG; Ryan, KR; Silinski, MA; Turner, KJ; Vallant, M; Waidyanatha, S, 2021) |
| "Hydroxyurea treatment downregulated the expression of Trp63 and upregulated Trp73 in the absence of effects on the levels of Trp53 transcripts; Trp73 upregulation was P53-dependent." | 1.48 | The Roles of P53 and Its Family Proteins, P63 and P73, in the DNA Damage Stress Response in Organogenesis-Stage Mouse Embryos. ( El Husseini, N; Hales, BF, 2018) |
| "Hydroxyurea has proven efficacy in numerous clinical trials as a disease-modifying treatment for patients with sickle cell anemia (SCA) but is currently under-used in clinical practice." | 1.42 | Optimizing hydroxyurea therapy for sickle cell anemia. ( Ware, RE, 2015) |
| "Diagnosis of post-PV myelofibrosis is established according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria." | 1.38 | How I treat polycythemia vera. ( Passamonti, F, 2012) |
| "On the other hand, CML and the treatment during pregnancy can have side effect on the mother and the fetus, so the patients should be monitored and treated in tertiary hospitals." | 1.36 | [Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia]. ( Liang, MY; Wang, DP; Wang, SM; Zhang, XH, 2010) |
| "Hydroxyurea is a drug used to treat cancer, sickle cell disease, and thalassemia." | 1.35 | NTP-CERHR monograph on the potential human reproductive and developmental effects of hydroxyurea. ( , 2008) |
| "Sickle cell disease is the most common inherited disease in the U." | 1.35 | The clinical care of adult patients with sickle cell disease. ( Howard, J; Olujohungbe, A, 2008) |
| " Dose-response relationships of skeleton variations and malformations induced by three antineoplastic drugs (FUDR: 5-fluoro-2'-deoxyuridine, HU: hydroxyurea and 6-MPr: 6-mercaptopurine-riboside) were evaluated." | 1.35 | Dose-response relationships of rat fetal skeleton variations: Relevance for risk assessment. ( Chahoud, I; Paumgartten, FJ, 2009) |
| "Hydroxyurea is a potent teratogen; free radical scavengers or antioxidants reduce its teratogenicity." | 1.33 | Activator protein-1 (AP-1) DNA binding activity is induced by hydroxyurea in organogenesis stage mouse embryos. ( Hales, BF; Yan, J, 2005) |
| "Diagnosis of polycythemia vera during pregnancy is a very difficult task due to physiologic changes occurring during gestation." | 1.32 | [Polycythemia vera and pregnancy]. ( Beillat, T; Dreyfus, M; Macro, M, 2004) |
| "Management of ET in pregnancy is still very much individualized." | 1.31 | Four pregnancies in two patients with essential thrombocythaemia--a case report. ( Devendra, K; Koh, LP; Tien, SL, 2002) |
| " From the dosage or exposure of laboratory animals, embryonic and maternal concentrations of the xenobiotic are calculated using a physiologically based pharmacokinetic (PBPK) model." | 1.30 | Mathematical analysis for teratogenic sensitivity. ( Luecke, RH; Wosilait, WD; Young, JF, 1997) |
| " Dose-response data of 6-MPr (s." | 1.30 | Combined prenatal toxicity of 6-mercaptopurine riboside and hydroxyurea in mice. ( Platzek, T; Schwabe, R, 1999) |
| " As a potent alternative to HAART, NNRTI's offer easier dosing and appear to have similar results, albeit in the short-term." | 1.30 | Antivirals update. ( , 1998) |
| "Hydroxyurea (HU) is a potent mammalian teratogen." | 1.29 | D-mannitol, a specific hydroxyl free radical scavenger, reduces the developmental toxicity of hydroxyurea in rabbits. ( Desesso, JM; Goeringer, GC; Scialli, AR, 1994) |
| "Surgery combined with chemotherapy was applied in 34 out of 178 patients (19." | 1.29 | Chemotherapy combined with surgery in the treatment of gestational trophoblastic disease (GTD). ( Kietlińska, Z; Sablińska, B; Zieliński, J, 1993) |
| "With bFGF, increased bone resorption was observed at 10(-9) M but not at 10(-8) M." | 1.28 | Effects of acid and basic fibroblast growth factor and heparin on resorption of cultured fetal rat long bones. ( Raisz, LG; Simmons, HA, 1991) |
| "Hydroxyurea (HU) is a swiftly acting cytotoxic teratogen and an inhibitor of DNA synthesis." | 1.28 | The nature of the embryo-protective interaction of propyl gallate with hydroxyurea. ( DeSesso, JM; Goeringer, GC, 1990) |
| " The results suggest that the antioxidant properties of these substances interfere with the rapidly occurring toxic effects of HU and that this may account for amelioration of HU developmental toxicity." | 1.28 | Ethoxyquin and nordihydroguaiaretic acid reduce hydroxyurea developmental toxicity. ( DeSesso, JM; Goeringer, GC, 1990) |
| "Timed-pregnant Fischer 344 rats were dosed by gavage with aniline hydrochloride (10, 30, or 100 mg/kg/day), a positive control agent (hydroxyurea, 200 mg/kg/day), or vehicle (distilled water) on gestational days (gd) 7 through 20 or gd 7 through parturition." | 1.27 | Teratologic and postnatal evaluation of aniline hydrochloride in the Fischer 344 rat. ( Ledoux, TA; Marks, TA; Paschke, LL; Price, CJ; Reel, JR; Tyl, RW, 1985) |
| " In our experimental conditions, the dose level of 300 mg/kg is regarded as a suitable positive control dosage in teratological testing of new molecules by oral route." | 1.26 | Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats. ( Aliverti, V; Bonanomi, L; Giavini, E, 1980) |
| "Aspirin was administered in single oral doses of 500 and 625 mg/kg on d 10; hydroxyurea was injected ip at 500 mg/kg on d 11." | 1.26 | Comparison of teratogenic effects of aspirin and hydroxyurea in the Fischer 344 and Wistar strains. ( DePass, LR; Weaver, EV, 1982) |
| "Hydroxyurea is a cytotoxic agent used in the management of chronic granulocytic leukemia." | 1.26 | Effects of hydroxyurea on hemodynamics of pregnant rabbits: a maternally mediated mechanism of embryotoxicity. ( Clark, KE; DeSesso, JM; Kleinman, LI; Millicovsky, G, 1981) |
| "Hydroxyurea (HU) is a potent teratogen which caused 100% embryotoxic effects in New Zealand white rabbits when injected sc on gestational day 12." | 1.26 | Amelioration of teratogenesis. I. Modification of hydroxyurea-induced teratogenesis by the antioxidant propyl gallate. ( DeSesso, JM, 1981) |
| "Hydroxyurea was administered intraperitoneally to pregnant albino rats in a single dose of 2000 mg/kg on day 14 of gestation." | 1.26 | Effects of hydroxyurea on postnatal growth and behaviour of rats. ( Fritz, H; Hess, R, 1980) |
| "Hydroxyurea is a drug which causes birth defects in a variety of animals." | 1.26 | Cell death and free radicals: a mechanism for hydroxyurea teratogenesis. ( DeSesso, JM, 1979) |
| "Hydroxyurea was given to pregnant rhesus monkeys and pregnant rats in regimens adjusted to produce similar degrees of teratogenicity, for the purpose of comparing the distribution of the drug in the females and their embryos." | 1.25 | Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys. ( Fradkin, R; Ritter, EJ; Scott, WJ; Wilson, JG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 80 (38.83) | 18.7374 |
| 1990's | 37 (17.96) | 18.2507 |
| 2000's | 48 (23.30) | 29.6817 |
| 2010's | 33 (16.02) | 24.3611 |
| 2020's | 8 (3.88) | 2.80 |
| Authors | Studies |
|---|---|
| Kroner, BL | 1 |
| Hankins, JS | 1 |
| Pugh, N | 1 |
| Kutlar, A | 1 |
| King, AA | 1 |
| Shah, NR | 1 |
| Kanter, J | 1 |
| Glassberg, J | 1 |
| Treadwell, M | 1 |
| Gordeuk, VR | 1 |
| Edahiro, Y | 1 |
| Qian, Y | 1 |
| Pei, Y | 1 |
| Jiang, W | 1 |
| Zheng, C | 1 |
| Askew, MA | 1 |
| Smaldone, AM | 1 |
| Gold, MA | 1 |
| Smith-Whitley, K | 2 |
| Strouse, JJ | 1 |
| Jin, Z | 1 |
| Green, NS | 1 |
| Guan, Z | 2 |
| Liang, Y | 1 |
| Wang, X | 2 |
| Zhu, Z | 2 |
| Yang, A | 1 |
| Li, S | 1 |
| Yu, J | 1 |
| Niu, B | 2 |
| Wang, J | 2 |
| Dong, M | 1 |
| Ware, RE | 4 |
| Dallmann, A | 1 |
| Vinks, AA | 1 |
| Schain, F | 1 |
| Vago, E | 1 |
| Song, C | 1 |
| He, J | 1 |
| Liwing, J | 1 |
| Löfgren, C | 1 |
| Björkholm, M | 1 |
| Huang, MC | 1 |
| Turner, KJ | 1 |
| Vallant, M | 1 |
| Robinson, VG | 1 |
| Lu, Y | 1 |
| Price, CJ | 3 |
| Fennell, TR | 1 |
| Silinski, MA | 1 |
| Waidyanatha, S | 1 |
| Ryan, KR | 1 |
| Black, SR | 1 |
| Fernando, RA | 1 |
| McIntyre, BS | 1 |
| Assi, R | 1 |
| Kantarjian, H | 1 |
| Keating, M | 1 |
| Pemmaraju, N | 1 |
| Verstovsek, S | 1 |
| Garcia-Manero, G | 1 |
| Ravandi, F | 1 |
| Borthakur, G | 1 |
| Dahl, J | 1 |
| Jabbour, E | 1 |
| Cortes, JE | 1 |
| Rodríguez-Vázquez, L | 3 |
| Martí, J | 4 |
| Ghafuri, DL | 1 |
| Stimpson, SJ | 1 |
| Day, ME | 1 |
| James, A | 1 |
| DeBaun, MR | 1 |
| Sharma, D | 1 |
| El Husseini, N | 2 |
| Hales, BF | 7 |
| Gwer, SO | 1 |
| Onyango, KO | 1 |
| Vons, O | 1 |
| Valero, O | 1 |
| Patel, S | 1 |
| Purohit, P | 1 |
| Jit, BP | 1 |
| Meher, S | 1 |
| Yahouédéhou, SCMA | 1 |
| da Guarda, CC | 1 |
| Figueiredo, CVB | 1 |
| Santiago, RP | 1 |
| Carvalho, SP | 1 |
| Fiuza, LM | 1 |
| Ndidi, US | 1 |
| Oliveira, RM | 1 |
| Carvalho, MOS | 1 |
| Nascimento, VML | 1 |
| Rocha, LC | 1 |
| Lyra, IM | 1 |
| Adorno, EV | 1 |
| Goncalves, MS | 1 |
| Deng, L | 2 |
| Zhang, J | 3 |
| Wu, T | 2 |
| Lawrie, TA | 1 |
| Alvarez-Larrán, A | 1 |
| Cervantes, F | 1 |
| Besses, C | 1 |
| Banh, S | 1 |
| Schlisser, AE | 2 |
| Álvarez-González, I | 1 |
| Vázquez-Sánchez, J | 2 |
| Chamorro-Cevallos, G | 2 |
| Madrigal-Bujaidar, E | 2 |
| Kreher, S | 1 |
| Ochsenreither, S | 1 |
| Trappe, RU | 1 |
| Pabinger, I | 1 |
| Bergmann, F | 1 |
| Petrides, PE | 3 |
| Koschmieder, S | 1 |
| Matzdorff, A | 1 |
| Tiede, A | 1 |
| Griesshammer, M | 2 |
| Riess, H | 1 |
| Dong, Y | 1 |
| Xu, L | 1 |
| Zhang, T | 1 |
| Chu, MM | 1 |
| Ma, Y | 1 |
| Tse, KY | 1 |
| Chan, KK | 1 |
| Ngan, HY | 1 |
| Faraci, M | 1 |
| Matthes-Martin, S | 1 |
| Lanino, E | 1 |
| Morreale, G | 1 |
| Ferretti, M | 1 |
| Giardino, S | 1 |
| Micalizzi, C | 1 |
| Balduzzi, A | 1 |
| Upadhye, DS | 1 |
| Jain, DL | 1 |
| Trivedi, YL | 1 |
| Nadkarni, AH | 2 |
| Ghosh, K | 2 |
| Colah, RB | 2 |
| Santa-Cruz, MC | 1 |
| Serra, R | 1 |
| Hervás, JP | 1 |
| Kingwell, K | 1 |
| Gerds, AT | 1 |
| Dao, KH | 1 |
| de Montalembert, M | 2 |
| Tshilolo, L | 1 |
| Abboud, MR | 1 |
| Birgegård, G | 1 |
| Dolai, TK | 1 |
| Bhargava, R | 1 |
| Mahapatra, M | 1 |
| Mishra, P | 1 |
| Seth, T | 1 |
| Pati, HP | 1 |
| Saxena, R | 1 |
| Olujohungbe, A | 1 |
| Howard, J | 1 |
| Braga, A | 1 |
| Maestá, I | 1 |
| Michelin, OC | 1 |
| Delmanto, LR | 1 |
| Consonni, M | 1 |
| Rudge, MV | 1 |
| Belfort, P | 1 |
| Yan, X | 1 |
| Girot, R | 1 |
| Stankovic, K | 1 |
| Lionnet, F | 1 |
| Wise, LD | 1 |
| Winkelmann, CT | 1 |
| Larouche, G | 1 |
| Chahoud, I | 2 |
| Paumgartten, FJ | 2 |
| Ramón-Gallegos, E | 1 |
| Mojica-Villegas, A | 1 |
| Pérez-Pastén-Borja, R | 1 |
| Tefferi, A | 3 |
| Passamonti, F | 2 |
| Italia, KY | 1 |
| Jijina, FF | 1 |
| Chandrakala, S | 1 |
| Sawant, P | 1 |
| Ballas, SK | 1 |
| McCarthy, WF | 1 |
| Guo, N | 1 |
| DeCastro, L | 1 |
| Bellevue, R | 1 |
| Barton, BA | 1 |
| Waclawiw, MA | 1 |
| Aygun, B | 1 |
| Harrison, C | 1 |
| Wang, DP | 1 |
| Liang, MY | 1 |
| Zhang, XH | 1 |
| Wang, SM | 1 |
| Barbui, T | 2 |
| Finazzi, G | 2 |
| Prochorec-Sobieszek, M | 1 |
| Nasiłowska-Adamska, B | 1 |
| Borg, K | 1 |
| Kopeć, I | 1 |
| Kos-Zakrzewska, K | 1 |
| Juszczyński, P | 1 |
| Warzocha, K | 1 |
| Lei, W | 1 |
| Feng, XH | 1 |
| Deng, WB | 1 |
| Ni, H | 1 |
| Zhang, ZR | 1 |
| Jia, B | 1 |
| Yang, XL | 1 |
| Wang, TS | 1 |
| Liu, JL | 1 |
| Su, RW | 1 |
| Liang, XH | 1 |
| Qi, QR | 1 |
| Yang, ZM | 1 |
| Campion, SN | 1 |
| Davenport, SJ | 1 |
| Nowland, WS | 1 |
| Cappon, GD | 1 |
| Bowman, CJ | 1 |
| Hurtt, ME | 1 |
| Kuriyama, SN | 1 |
| Tsimberidou, AM | 1 |
| Giles, FJ | 1 |
| Halsey, C | 1 |
| Roberts, IA | 1 |
| Woo, GH | 3 |
| Katayama, K | 2 |
| Jung, JY | 1 |
| Uetsuka, K | 2 |
| Bak, EJ | 3 |
| Nakayama, H | 3 |
| Doi, K | 3 |
| Al-Zahrani, H | 1 |
| Gupta, V | 1 |
| Minden, MD | 1 |
| Messner, HA | 1 |
| Lipton, JH | 2 |
| Gupta, C | 1 |
| Yaffe, SJ | 1 |
| Barosi, G | 1 |
| Grossi, A | 1 |
| Gugliotta, L | 1 |
| Liberato, LN | 1 |
| Marchetti, M | 1 |
| Mazzucconi, MG | 1 |
| Rodeghiero, F | 1 |
| Tura, S | 1 |
| Pata, O | 1 |
| Tok, CE | 1 |
| Yazici, G | 1 |
| Pata, C | 1 |
| Oz, AU | 1 |
| Aban, M | 1 |
| Dilek, S | 1 |
| Green, AR | 1 |
| Vassiliou, GS | 1 |
| Curtin, N | 1 |
| Campbell, PJ | 1 |
| Beillat, T | 1 |
| Macro, M | 1 |
| Dreyfus, M | 1 |
| Ueno, M | 1 |
| Yamauchi, H | 1 |
| Yan, J | 2 |
| Paul, SR | 1 |
| Balasooriya, U | 1 |
| Banerjee, T | 1 |
| Xue, Y | 1 |
| Wu, TX | 1 |
| An, RF | 1 |
| Rogers, ZR | 1 |
| Liebelt, EL | 1 |
| Balk, SJ | 1 |
| Faber, W | 1 |
| Fisher, JW | 1 |
| Hughes, CL | 1 |
| Lanzkron, SM | 1 |
| Lewis, KM | 1 |
| Marchetti, F | 1 |
| Mehendale, HM | 1 |
| Rogers, JM | 3 |
| Shad, AT | 1 |
| Skalko, RG | 3 |
| Stanek, EJ | 1 |
| Reilly, JT | 1 |
| Soukup, S | 1 |
| Takacs, E | 1 |
| Warkany, J | 1 |
| Bagshawe, KD | 3 |
| Ghosh, NK | 1 |
| Weed, JC | 1 |
| Barnard, DE | 1 |
| Currie, JL | 1 |
| Clayton, LA | 1 |
| Hammond, CB | 2 |
| Kröger, H | 1 |
| Grätz, R | 1 |
| Ritter, EJ | 7 |
| Johnson, RT | 1 |
| Collins, AR | 1 |
| Elliott, GC | 1 |
| Squires, S | 1 |
| Scott, WJ | 6 |
| Wilson, JG | 5 |
| Mathinos, PR | 1 |
| Randall, JL | 1 |
| Bertoli, D | 1 |
| Borelli, G | 1 |
| Herken, R | 2 |
| Shekhter-Levin, S | 1 |
| Amato, D | 1 |
| Axelrad, AA | 1 |
| Warner, CW | 1 |
| Sadler, TW | 1 |
| Shockey, J | 1 |
| Smith, MK | 1 |
| Yu, YN | 1 |
| Ding, C | 1 |
| Li, QG | 1 |
| Chen, XR | 1 |
| Amortegui, AJ | 2 |
| Klionsky, B | 2 |
| Surti, U | 1 |
| Coyne, A | 1 |
| Seller, MJ | 2 |
| Perkins, KJ | 1 |
| Kwasigroch, TE | 2 |
| Aliverti, V | 1 |
| Bonanomi, L | 1 |
| Giavini, E | 1 |
| Le Bouteiller, PP | 1 |
| Asherson, GL | 1 |
| Kanamaru, A | 1 |
| Okamoto, T | 1 |
| Hara, H | 1 |
| Nagai, K | 1 |
| Sugrue, SP | 1 |
| Desesso, JM | 10 |
| DePass, LR | 1 |
| Weaver, EV | 1 |
| Millicovsky, G | 2 |
| Kleinman, LI | 1 |
| Clark, KE | 1 |
| Barr, M | 1 |
| Beaudoin, AR | 1 |
| Fritz, H | 1 |
| Hess, R | 1 |
| Inhorn, RC | 1 |
| Aster, JC | 1 |
| Roach, SA | 1 |
| Slapak, CA | 1 |
| Soiffer, R | 1 |
| Tantravahi, R | 1 |
| Stone, RM | 1 |
| Jakó, J | 1 |
| Cinkotai, KI | 1 |
| Wood, P | 1 |
| Donnai, P | 1 |
| Kendra, J | 1 |
| Scialli, AR | 1 |
| Goeringer, GC | 3 |
| Fernandez, H | 1 |
| Sablińska, B | 1 |
| Kietlińska, Z | 1 |
| Zieliński, J | 1 |
| Goldman, JM | 1 |
| Jackson, N | 1 |
| Shukri, A | 1 |
| Ali, K | 1 |
| Liang, KY | 1 |
| McCullagh, P | 1 |
| Szántó, F | 1 |
| Kovács, L | 1 |
| Fitzgerald, JM | 1 |
| McCann, SR | 1 |
| Heimpel, H | 1 |
| Pearson, TC | 1 |
| Derzko, CM | 1 |
| Curtis, J | 1 |
| Armenta, D | 1 |
| Espallargas, C | 1 |
| Paz, A | 1 |
| Rodríguez Martorel, J | 1 |
| Ladines, R | 1 |
| Alvarez, C | 1 |
| Román, J | 1 |
| Andrés, P | 1 |
| Dell'Isola, A | 1 |
| Di Rosa, G | 1 |
| Catalano, D | 1 |
| Luecke, RH | 1 |
| Wosilait, WD | 1 |
| Young, JF | 1 |
| Ohene-Frempong, K | 1 |
| Terasako, K | 1 |
| Sasai, S | 1 |
| Zucker, RM | 2 |
| Hunter, S | 1 |
| Bower, M | 1 |
| Rustin, GJ | 1 |
| Newlands, ES | 1 |
| Holden, L | 1 |
| Short, D | 1 |
| Foskett, M | 1 |
| Diav-Citrin, O | 1 |
| Hunnisett, L | 1 |
| Sher, GD | 1 |
| Koren, G | 1 |
| Platzek, T | 1 |
| Schwabe, R | 1 |
| Hunter, ES | 1 |
| Bégué, P | 1 |
| Bernaudin, F | 1 |
| Thuret, I | 1 |
| Bachir, D | 1 |
| Micheau, M | 1 |
| Knutsen, H | 1 |
| Bruserud, O | 1 |
| Byrd, DC | 1 |
| Pitts, SR | 1 |
| Alexander, CK | 1 |
| Fiorani, C | 1 |
| Tonelli, S | 1 |
| Casolari, B | 1 |
| Sacchi, S | 1 |
| Randi, ML | 1 |
| Rossi, C | 1 |
| Fabris, F | 1 |
| Girolami, A | 1 |
| Baykal, C | 1 |
| Zengin, N | 1 |
| Coşkun, F | 1 |
| Güler, N | 1 |
| Ayhan, A | 1 |
| Polák, J | 1 |
| Koza, V | 1 |
| Cetkovský, P | 1 |
| Haskovec, C | 1 |
| Solberg, LA | 1 |
| Silverstein, MN | 1 |
| Celiloglu, M | 1 |
| Altunyurt, S | 1 |
| Undar, B | 1 |
| Briere, J | 1 |
| Guilmin, F | 1 |
| Wright, CA | 1 |
| Thauvin-Robinet, C | 1 |
| Maingueneau, C | 1 |
| Robert, E | 1 |
| Elefant, E | 2 |
| Guy, H | 1 |
| Caillot, D | 1 |
| Casasnovas, RO | 1 |
| Douvier, S | 1 |
| Nivelon-Chevallier, A | 1 |
| Reed, W | 1 |
| Vichinsky, EP | 1 |
| Fadilah, SA | 1 |
| Ahmad-Zailani, H | 1 |
| Soon-Keng, C | 1 |
| Norlaila, M | 1 |
| Koh, LP | 1 |
| Devendra, K | 1 |
| Tien, SL | 1 |
| Arfellini, G | 1 |
| Grilli, S | 1 |
| Prodi, G | 1 |
| Azizkhan, JC | 1 |
| Speeg, KV | 1 |
| Stromberg, K | 1 |
| Goode, D | 1 |
| Surwit, EA | 1 |
| Suciu, TN | 1 |
| Schmidt, HJ | 1 |
| Rosendaal, M | 1 |
| Piver, MS | 1 |
| Barlow, JJ | 1 |
| Vongtama, V | 1 |
| Blumenson, L | 1 |
| Rich, KA | 2 |
| Kerr, JB | 1 |
| de Kretser, DM | 2 |
| Khera, KS | 1 |
| Theisen, CT | 1 |
| Bodell, WJ | 1 |
| Banerjee, MR | 1 |
| Brunner, RL | 1 |
| McLean, M | 1 |
| Vorhees, CV | 1 |
| Butcher, RE | 2 |
| Jordan, RL | 1 |
| Kester, MV | 1 |
| Jacobson, EL | 1 |
| Gracy, RW | 1 |
| Rich, IN | 1 |
| Kubanek, B | 1 |
| Feinberg, SS | 1 |
| Figallo, EM | 1 |
| Fradkin, R | 1 |
| Krowke, R | 1 |
| Bochert, G | 1 |
| Adlard, BP | 1 |
| Dobbing, J | 1 |
| Miller, SA | 1 |
| Runner, MN | 1 |
| Ranney, HM | 1 |
| Delmer, A | 1 |
| Rio, B | 1 |
| Bauduer, F | 1 |
| Ajchenbaum, F | 1 |
| Marie, JP | 1 |
| Zittoun, R | 1 |
| Tertian, G | 1 |
| Tchernia, G | 1 |
| Papiernik, E | 1 |
| Simmons, HA | 1 |
| Raisz, LG | 2 |
| Patel, M | 1 |
| Dukes, IA | 1 |
| Hull, JC | 1 |
| Schafer, AI | 1 |
| Curry, SL | 1 |
| Blessing, JA | 1 |
| DiSaia, PJ | 1 |
| Soper, JT | 1 |
| Twiggs, LB | 1 |
| Bolis, G | 1 |
| Bonazzi, C | 1 |
| Landoni, F | 1 |
| Mangili, G | 1 |
| Vergadoro, F | 1 |
| Zanaboni, F | 1 |
| Mangioni, C | 1 |
| Wong, LC | 1 |
| Choo, YC | 1 |
| Ma, HK | 1 |
| Lorenzo, JA | 1 |
| Quinton, J | 1 |
| Sousa, S | 1 |
| Boden, J | 1 |
| Boxer, GM | 1 |
| Britton, DW | 1 |
| Green, A | 1 |
| Partridge, T | 1 |
| Pedley, B | 1 |
| Sharma, S | 1 |
| Southall, P | 1 |
| Asano, Y | 1 |
| Okaniwa, A | 1 |
| Tyl, RW | 2 |
| Marks, TA | 2 |
| Paschke, LL | 2 |
| Ledoux, TA | 2 |
| Reel, JR | 2 |
| Roll, R | 1 |
| Bär, F | 1 |
| Hervet, E | 1 |
| Barrat, J | 1 |
| Darbois, Y | 1 |
| Faguer, C | 1 |
| Jusko, WJ | 1 |
| Chaube, S | 1 |
| Murphy, ML | 1 |
| Kazmaier, K | 1 |
| Salaman, DF | 1 |
| Birkett, S | 1 |
| Bourne, RA | 1 |
| Bryant, JA | 1 |
| Falconer, IR | 1 |
| von Kreybig, T | 3 |
| Rajewsky, MF | 1 |
| Fabricius, E | 1 |
| Hülser, DF | 1 |
| Haas, RJ | 2 |
| Green, CD | 1 |
| Skarda, J | 1 |
| Barry, JM | 3 |
| Schreiner, L | 1 |
| Mayne, R | 1 |
| Roba, J | 1 |
| Lambelin, G | 1 |
| Buu-Hoï, NP | 1 |
| Wigglesworth, JS | 1 |
| Bohne, F | 1 |
| Fliedner, TM | 1 |
| Fache, I | 1 |
| Preussmann, R | 1 |
| Schmidt, W | 1 |
| Leader, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial[NCT00816114] | 3,000 participants (Anticipated) | Observational | 2005-06-08 | Recruiting | |||
| A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults[NCT05378555] | Phase 3 | 10 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)[NCT04839159] | 41 participants (Anticipated) | Interventional | 2012-05-10 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
40 reviews available for hydroxyurea and Pregnancy
| Article | Year |
|---|---|
Treatment options and pregnancy management for patients with PV and ET.
Topics: Aspirin; Female; Humans; Hydroxyurea; Janus Kinase 2; Janus Kinase Inhibitors; Myeloproliferative Di | 2022 |
Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps.
Topics: Adult; Anemia, Sickle Cell; Animals; Antisickling Agents; Child; Female; Humans; Hydroxyurea; Infant | 2023 |
Fertility challenges for women with sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Chronic Pain; Female; Fertility; Fertility Preservation; Gen | 2017 |
An Animal Model for Assessing the Effects of Hydroxyurea Exposure Suggests That the Administration of This Agent to Pregnant Women and Young Infants May Not Be as Safe as We Thought.
Topics: Apoptosis; Cell Cycle; Cell Death; Cerebellum; Female; Humans; Hydroxyurea; Immunohistochemistry; In | 2018 |
Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Doxorubicin; Early T | 2013 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
Polycythemia Vera Management and Challenges in the Community Health Setting.
Topics: Community Health Centers; Drug Resistance, Neoplasm; Elective Surgical Procedures; Female; Hematocri | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Chronic Dise | 2017 |
Long-term management of thrombocytosis in essential thrombocythaemia.
Topics: Algorithms; Antineoplastic Agents; Aspirin; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Interf | 2009 |
Combination chemotherapy for high-risk gestational trophoblastic tumour.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Doxorubicin; Female; | 2009 |
[New issues in adult sickle sell disease].
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Cardiomyopathies; Combined Modality Therapy; Female; | 2008 |
Advances in the use of hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Animals; Arterial Occlusive Diseases; Bone Marrow Diseases; Child; Clini | 2009 |
Do we know more about essential thrombocythemia because of JAK2V617F?
Topics: Female; Humans; Hydroxyurea; Janus Kinase 2; Polycythemia Vera; Pregnancy; Pregnancy Complications; | 2009 |
Special issues in myeloproliferative neoplasms.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Child; Female; Hemorrhage; Humans; Hydroxyur | 2011 |
How to manage essential thrombocythemia.
Topics: Female; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Interferon-alpha; Pregnancy; Pregnancy C | 2012 |
Essential thrombocythemia (ET): moving from palliation to cure.
Topics: Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Male; Palliative Care; Pregnancy; | 2002 |
The role of hydroxyurea in sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Cell Communicat | 2003 |
Vascular events associated with alpha interferon therapy.
Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Foot Ulcer; Gangrene; Hemolytic-Uremic Syndrome | 2003 |
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Cell Transformation, Neoplastic; Child; Clinical Tria | 2004 |
Management of the myeloproliferative disorders : distinguishing data from dogma.
Topics: Abnormalities, Drug-Induced; Adult; Aged; Anticoagulants; Contraindications; Female; Humans; Hydroxy | 2004 |
Anagrelide: what was new in 2004 and 2005?
Topics: Antineoplastic Agents; Aspirin; Blood Platelets; Clinical Trials, Phase III as Topic; Drug Therapy, | 2006 |
Combination chemotherapy for high-risk gestational trophoblastic tumour.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Doxorubicin; Female; | 2006 |
[Primary thrombocythemia: diagnosis and therapy].
Topics: Adult; Aged; Aspirin; Child; Diagnosis, Differential; Drug Therapy, Combination; Enzyme Inhibitors; | 2006 |
Review: clinical transfusion management in sickle cell disease.
Topics: Anemia, Sickle Cell; Blood Transfusion; Disease Management; Erythrocyte Transfusion; Female; Humans; | 2006 |
NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea.
Topics: Animals; Drug Administration Routes; Embryonic Development; Female; Humans; Hydroxyurea; Male; Natio | 2007 |
Treatment of high-risk choriocarcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Chorionic Gonadotropin; Cycl | 1984 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 1995 |
Management of chronic myeloid leukaemia.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Blast Crisis; Bone Marrow Transplantation; Busulfan; Ch | 1994 |
Essential thrombocythemia and pregnancy.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Aspirin; Busulfan; Combined Modality Therapy; Di | 1996 |
Use of hydroxyurea in children with sickle cell disease: what comes next?
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Contraindications; Female; Fetal Hemoglobin; | 1997 |
Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature.
Topics: Adult; Anemia, Sickle Cell; Female; Gestational Age; Humans; Hydroxyurea; Infant, Newborn; Male; Pre | 1999 |
[A management program for primary thrombocytopenia].
Topics: Adult; Aged; Anticoagulants; Aspirin; Female; Guidelines as Topic; Humans; Hydroxyurea; Interferon T | 1999 |
The role of interferon-alpha in the treatment of myeloproliferative disorders.
Topics: Clinical Trials as Topic; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interf | 1999 |
A clinical update in polycythemia vera and essential thrombocythemia.
Topics: Age Factors; Carcinogens; Cell Transformation, Neoplastic; Chronic Disease; Enzyme Inhibitors; Femal | 2000 |
Management of patients with essential thrombocythemia: current concepts and perspectives.
Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr | 2001 |
A single institutional experience with 43 pregnancies in essential thrombocythemia.
Topics: Abortion, Induced; Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Aspirin; Busulf | 2001 |
Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Bacteremia; Blood Group Antigens; Blood Substitutes; B | 2001 |
The spectrum of sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Azacitidine; Chromosomes, Human, Pair 11; Chromosomes, Human | 1992 |
Essential thrombocythemia.
Topics: Abortion, Habitual; Age Factors; Blood Platelets; Combined Modality Therapy; Diagnosis, Differential | 1991 |
[Carcinogenesis and teratogenesis. Comparative studies from the viewpoint of teratology].
Topics: Abnormalities, Drug-Induced; Alkylating Agents; Animals; Antineoplastic Agents; Carcinogens; Cycloph | 1970 |
6 trials available for hydroxyurea and Pregnancy
| Article | Year |
|---|---|
Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway.
Topics: Aged; Busulfan; Danazol; Disease-Free Survival; Female; Follow-Up Studies; Glucocorticoids; Humans; | 2019 |
Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with βS haplotype and α-thalassemia.
Topics: alpha-Thalassemia; Anemia, Sickle Cell; Bilirubin; Biomarkers; Blood Glucose; Child; Child, Preschoo | 2019 |
Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Female; Fetus; Humans; Hydroxyurea; Male; Pregnancy; Pregn | 2009 |
Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix.
Topics: Clinical Trials as Topic; Double-Blind Method; Female; Hematopoiesis; Humans; Hydroxyurea; Lymphatic | 1977 |
Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report.
Topics: Adult; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Pre | 1991 |
A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease:
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Dactinomycin; | 1989 |
160 other studies available for hydroxyurea and Pregnancy
| Article | Year |
|---|---|
Pregnancy outcomes with hydroxyurea use in women with sickle cell disease.
Topics: Abortion, Spontaneous; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Infant; Infant, Newborn; Li | 2022 |
Astilbin improves pregnancy outcome in rats with recurrent spontaneous abortion by regulating Th1/Th2 balance.
Topics: Abortion, Spontaneous; Animals; Female; Flavonols; Humans; Hydroxyurea; Interleukin-10; Interleukin- | 2022 |
Pediatric hematology providers' contraceptive practices for female adolescents and young adults with sickle cell disease: A national survey.
Topics: Adolescent; Anemia, Sickle Cell; Child; Contraception; Contraceptive Agents; Female; Hematology; Hum | 2022 |
Unraveling the Mechanisms of Clinical Drugs-Induced Neural Tube Defects Based on Network Pharmacology and Molecular Docking Analysis.
Topics: Animals; Anticonvulsants; Antineoplastic Agents; Class I Phosphatidylinositol 3-Kinases; ErbB Recept | 2022 |
Tolerability and age-dependent toxicokinetics following perinatal hydroxyurea treatment in Sprague Dawley rats.
Topics: Animals; Animals, Newborn; Antisickling Agents; Body Weight; Female; Hydroxyurea; Lactation; Male; P | 2021 |
Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.
Topics: Blast Crisis; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; P | 2021 |
Effects of Hydroxyurea Exposure on the Rat Cerebellar Neuroepithelium: an Immunohistochemical and Electron Microscopic Study Along the Anteroposterior and Mediolateral Axes.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Nucleus; Cerebellum; Female; Fetus; Hydroxyurea; Imm | 2017 |
The Roles of P53 and Its Family Proteins, P63 and P73, in the DNA Damage Stress Response in Organogenesis-Stage Mouse Embryos.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; DNA Damage; Embryo, Mammalian; Female; Humans; Hydroxyur | 2018 |
Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol.
Topics: Anemia, Sickle Cell; Antisickling Agents; Congenital Abnormalities; Female; Humans; Hydroxyurea; Inc | 2018 |
Hydroxyurea Exposure and Development of the Cerebellar External Granular Layer: Effects on Granule Cell Precursors, Bergmann Glial and Microglial Cells.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Cerebellum; Female; Hydroxyurea; Male; Microglia; | 2019 |
Pregnancy outcomes in women with sickle cell disease: a retrospective study from Eastern India.
Topics: Abortion, Induced; Abortion, Spontaneous; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusio | 2019 |
Hydroxyurea exposure triggers tissue-specific activation of p38 mitogen-activated protein kinase signaling and the DNA damage response in organogenesis-stage mouse embryos.
Topics: Abnormalities, Drug-Induced; Animals; Cell Nucleus; Cytoplasm; DNA; DNA Damage; Dose-Response Relati | 2013 |
Deprenyl enhances the teratogenicity of hydroxyurea in organogenesis stage mouse embryos.
Topics: Animals; Drug Synergism; Embryo, Mammalian; Female; Hydroxyurea; Mice; Monoamine Oxidase Inhibitors; | 2013 |
Effect of Spirulina maxima and its protein extract on micronuclei induction by hydroxyurea in pregnant mice and their fetuses.
Topics: Animals; Antimutagenic Agents; DNA Damage; Dose-Response Relationship, Drug; Erythrocytes; Female; F | 2013 |
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncolo
Topics: Anticoagulants; Disease Susceptibility; Drug Interactions; Female; Hemorrhage; Heparin, Low-Molecula | 2014 |
dNTP deficiency induced by HU via inhibiting ribonucleotide reductase affects neural tube development.
Topics: Abnormalities, Drug-Induced; Animals; Apoptosis; Brain; Caspase 3; Cell Proliferation; Deoxyribonucl | 2015 |
Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Female; Gesta | 2015 |
Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia.
Topics: Adolescent; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Drug Administration Schedule; F | 2016 |
Optimizing hydroxyurea therapy for sickle cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cerebrovascular Disorders; Drug Adminis | 2015 |
Neonatal Screening and the Clinical Outcome in Children with Sickle Cell Disease in Central India.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Female; Heterozygote; Homozygote; Humans | 2016 |
Editor's Highlight: Hydroxyurea Exposure Activates the P53 Signaling Pathway in Murine Organogenesis-Stage Embryos.
Topics: Animals; Blotting, Western; Embryo, Mammalian; Female; Hydroxyurea; Mice; Oligonucleotide Array Sequ | 2016 |
Hydroxyurea Treatment and Development of the Rat Cerebellum: Effects on the Neurogenetic Profiles and Settled Patterns of Purkinje Cells and Deep Cerebellar Nuclei Neurons.
Topics: Analysis of Variance; Animals; Cerebellum; Disease Models, Animal; Dose-Response Relationship, Drug; | 2016 |
Sickle cell solutions in sight.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials, Phase III as Topic; Female; Hemogl | 2016 |
Is imatinib safe during pregnancy?
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, | 2009 |
The clinical care of adult patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Genetic Testing; Heart Diseases; Humans; Hy | 2008 |
Maternal and perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia in Brazilian women.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brazil; Cisplatin; Cohort Studies; Cyclophosphamide; | 2009 |
NTP-CERHR monograph on the potential human reproductive and developmental effects of hydroxyurea.
Topics: Animals; Carcinogenicity Tests; Dose-Response Relationship, Drug; Female; Fetus; Humans; Hydroxyurea | 2008 |
Evaluation of hydroxyurea-induced fetal skeletal changes in Dutch belted rabbits by micro-computed tomography and alizarin red staining.
Topics: Animals; Anthraquinones; Bone and Bones; Bone Diseases, Developmental; Cesarean Section; Coloring Ag | 2009 |
The impact of human superoxide dismutase 1 expression in a mouse model on the embryotoxicity of hydroxyurea.
Topics: Abnormalities, Drug-Induced; Animals; Bone and Bones; Disease Models, Animal; Enzyme Inhibitors; Fem | 2009 |
Dose-response relationships of rat fetal skeleton variations: Relevance for risk assessment.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Dose-Response Relationship, Drug; Female; Floxuridin | 2009 |
Spirulina maxima and its protein extract protect against hydroxyurea-teratogenic insult in mice.
Topics: Animals; Dose-Response Relationship, Drug; Female; Hydroxyurea; Mice; Plant Extracts; Plant Proteins | 2009 |
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations.
Topics: Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Interferon Type I; Pregnancy; P | 2009 |
Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Female; Fetus; Humans; Hydroxyure | 2010 |
[Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy, Needle; Female; Follow-Up Studies; Humans; Hydroxy | 2010 |
Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?
Topics: Antineoplastic Agents; Cell Proliferation; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; C | 2012 |
Progesterone and DNA damage encourage uterine cell proliferation and decidualization through up-regulating ribonucleotide reductase 2 expression during early pregnancy in mice.
Topics: Animals; Blotting, Western; Cell Proliferation; Cells, Cultured; Decidua; DNA Damage; E2F1 Transcrip | 2012 |
Sensitive windows of skeletal development in rabbits determined by hydroxyurea exposure at different times throughout gestation.
Topics: Animals; Bone and Bones; Bone Development; Cesarean Section; Craniofacial Abnormalities; Female; Fet | 2012 |
How I treat polycythemia vera.
Topics: Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Janus Kinase 2; Janus Kinases; Ma | 2012 |
Maternal protein-and-energy restriction reduces the developmental toxicity of cyclophosphamide and hydroxyurea in rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Body Weight; Cyclophosphamide; Di | 2002 |
Hydroxyurea (HU)-induced apoptosis in the mouse fetal tissues.
Topics: Animals; Antineoplastic Agents; Apoptosis; Coloring Agents; DNA Fragmentation; Epithelial Cells; Fem | 2003 |
Phenobarbital-induced alterations in the sexual differentiation of the female rat: reversal by hydroxyurea and cycloheximide.
Topics: Animals; Cycloheximide; Estrous Cycle; Female; Fertility; Hydroxyurea; Phenobarbital; Pregnancy; Pre | 1982 |
Polycythemia vera and pregnancy: a case report with the use of hydroxyurea in the first trimester.
Topics: Adult; Antineoplastic Agents; Diagnosis, Differential; Female; Humans; Hydroxyurea; Infant, Newborn; | 2004 |
[Polycythemia vera and pregnancy].
Topics: Adult; Antisickling Agents; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hum | 2004 |
Effects of prenatal hydroxyurea-treatment on mouse offspring.
Topics: Abnormalities, Drug-Induced; Animals; Apoptosis; Female; Fetus; Hydroxyurea; Male; Mice; Mice, Inbre | 2004 |
Activator protein-1 (AP-1) DNA binding activity is induced by hydroxyurea in organogenesis stage mouse embryos.
Topics: Animals; Bone and Bones; DNA; Electrophoretic Mobility Shift Assay; Embryonic Development; Enzyme-Li | 2005 |
Hydroxyurea (HU)-induced apoptosis in the mouse fetal lung.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Cycle; Female; Fetus; Flow Cyto | 2005 |
Fisher information matrix of the Dirichlet-multinomial distribution.
Topics: Abnormalities, Drug-Induced; Animals; Biometry; Data Interpretation, Statistical; Female; Hydroxyure | 2005 |
Depletion of glutathione induces 4-hydroxynonenal protein adducts and hydroxyurea teratogenicity in the organogenesis stage mouse embryo.
Topics: Abnormalities, Drug-Induced; Aldehydes; Animals; Buthionine Sulfoximine; DNA; Embryo, Mammalian; Fem | 2006 |
Practical approach to treating essential thrombocythaemia: case studies.
Topics: Adult; Aspirin; Disease Management; Female; Humans; Hydroxyurea; Interferon-alpha; Leg Ulcer; Male; | 2007 |
Chromosome changes in embryos treated with various teratogens.
Topics: Abnormalities, Drug-Induced; Animals; Chlorambucil; Chromosome Aberrations; Diet; Female; Hydroxyure | 1967 |
Drug-induced biochemical markers of cancer in cervical carcinoma cells.
Topics: Alkaline Phosphatase; Butyrates; Butyric Acid; Carcinoembryonic Antigen; Chorionic Gonadotropin; Cho | 1982 |
Chemotherapy with the modified Bagshawe protocol for poor prognosis metastatic trophoblastic disease.
Topics: Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Administration Schedule; Dr | 1982 |
[Effect of L-tryptophan, nicotinamide, L-methionine and 1-methylnicotinamide on the embryotoxic effect of various substances].
Topics: 6-Aminonicotinamide; Animals; Cyclophosphamide; Drug Interactions; Embryo, Mammalian; Female; Hydrox | 1983 |
Potentiation of teratogenesis.
Topics: Animals; Antibiotics, Antineoplastic; Cytarabine; DNA; Drug Synergism; Embryo, Mammalian; Female; Fl | 1984 |
Comparative studies of repair using inhibitors.
Topics: Animals; Arvicolinae; Bloom Syndrome; Cell Line; Cells, Cultured; Cytarabine; DNA Repair; Dose-Respo | 1984 |
Potentiative interactions between caffeine and various teratogenic agents.
Topics: Abnormalities, Drug-Induced; Acetazolamide; Animals; Caffeine; Cycloheximide; Dactinomycin; Dose-Res | 1982 |
[Teratogenic action of Rifaximin in the rat and rabbit and its effect on perinatal development in the rat].
Topics: Abnormalities, Drug-Induced; Animals; Female; Fetus; Hydroxyurea; Pregnancy; Prenatal Exposure Delay | 1984 |
The influence of deoxycytidine monophosphate (dCMP) on the cytotoxicity of hydroxyurea in the embryonic spinal cord of the mouse.
Topics: Abnormalities, Drug-Induced; Animals; Deoxycytidine Monophosphate; Deoxycytosine Nucleotides; Drug I | 1984 |
The proliferative state of early erythropoietic progenitor cells (BFU-E) in human umbilical cord blood: low probability of finding BFU-E in DNA synthesis.
Topics: Cell Division; Cell Survival; Cells, Cultured; DNA Replication; Erythropoiesis; Female; Fetal Blood; | 1984 |
A comparison of the in vivo and in vitro response of mammalian embryos to a teratogenic insult.
Topics: Abnormalities, Drug-Induced; Animals; Culture Techniques; Embryo, Mammalian; Female; Gestational Age | 1983 |
A modified method of UDS detection in vitro suitable for screening the DNA-damaging effects of chemicals.
Topics: Amnion; Carcinogens; Cell Line; DNA Replication; Female; Humans; Hydroxyurea; Kinetics; Mutagenicity | 1983 |
Experimental intrauterine fetal growth retardation in the rat: effect of a single dose of hydroxyurea or cycloheximide on the fetus at term.
Topics: Animals; Brain; Cycloheximide; DNA; Female; Fetal Growth Retardation; Hydroxyurea; Kidney; Liver; Mo | 1983 |
Effect of hydroxyurea on neural tube defects in the curly-tail mouse.
Topics: Animals; Female; Fetal Resorption; Hydroxyurea; Male; Mice; Mice, Neurologic Mutants; Neural Tube De | 1983 |
The interaction of chemicals during pregnancy: an update.
Topics: Abnormalities, Drug-Induced; Animals; Bromodeoxyuridine; Caffeine; Drug Interactions; Female; Fetus; | 1983 |
The cause of neural tube defects: some experiments and a hypothesis.
Topics: Animals; Disease Models, Animal; DNA; Female; Fluorouracil; Gestational Age; Hydroxyurea; Mice; Mice | 1983 |
Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Embryo, Mammalian; Female; Gestational A | 1980 |
Regulation of B cell development in mouse bone marrow.
Topics: Animals; B-Lymphocytes; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Female; Hydroxyurea; L | 1982 |
Developmental changes in erythropoietin responsiveness of late erythroid precursors in mouse hemopoietic organs.
Topics: Animals; Animals, Newborn; Cells, Cultured; Embryo, Mammalian; Erythropoiesis; Erythropoietin; Femal | 1982 |
Altered glycosaminoglycan composition of rat forelimb-buds during hydroxyurea teratogenesis: an indication of repair.
Topics: Abnormalities, Drug-Induced; Animals; Cell Survival; Female; Forelimb; Glycosaminoglycans; Hydroxyur | 1982 |
Comparison of teratogenic effects of aspirin and hydroxyurea in the Fischer 344 and Wistar strains.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Female; Hydroxyurea; Pregnancy; Rats; Rats, Inbred F3 | 1982 |
Effects of hydroxyurea on hemodynamics of pregnant rabbits: a maternally mediated mechanism of embryotoxicity.
Topics: Abnormalities, Drug-Induced; Animals; Blood Pressure; Female; Heart Rate; Hydroxyurea; Pregnancy; Pr | 1981 |
Comparative ultrastructural alterations in rabbit limb-buds after a teratogenic dose of either hydroxyurea or methotrexate.
Topics: Animals; Female; Germ Layers; Hydroxyurea; Methotrexate; Microscopy, Electron; Pregnancy; Rabbits; T | 1981 |
Amelioration of teratogenesis. I. Modification of hydroxyurea-induced teratogenesis by the antioxidant propyl gallate.
Topics: Abnormalities, Drug-Induced; Animals; Bone and Bones; Female; Gallic Acid; Gestational Age; Hydroxyu | 1981 |
An exploration of the role of hydroxyurea injection time in fetal growth and teratogenesis in rats.
Topics: Abnormalities, Drug-Induced; Animals; Circadian Rhythm; Female; Fetal Resorption; Fetus; Growth; Hyd | 1981 |
Cell cycle phase specificity of hydroxyurea and its effects on the cell kinetics in embryonic spinal cord.
Topics: Animals; Cell Cycle; DNA Replication; Female; Gestational Age; Hydroxyurea; Interphase; Kinetics; Mi | 1980 |
Cardiovascular alterations in rabbit embryos in situ after a teratogenic dose of hydroxyurea: an in vivo microscopic study.
Topics: Animals; Cardiac Tamponade; Cardiovascular System; Cerebral Hemorrhage; Embryo, Mammalian; Female; H | 1980 |
Effects of hydroxyurea on postnatal growth and behaviour of rats.
Topics: Animals; Animals, Newborn; Body Weight; Brain; Female; Fertility; Fetus; Hydroxyurea; Male; Motor Ac | 1980 |
[Leukemia, cytostatic therapy and pregnancy].
Topics: Antineoplastic Agents; Cytogenetics; Female; Humans; Hydroxyurea; Infant, Newborn; Leukemia, Myeloge | 1994 |
Pregnancy after treatment with hydroxyurea in a patient with primary thrombocythaemia and a history of recurrent abortion.
Topics: Abortion, Habitual; Adult; Blood Platelets; Female; Humans; Hydroxyurea; Pregnancy; Pregnancy Compli | 1994 |
D-mannitol, a specific hydroxyl free radical scavenger, reduces the developmental toxicity of hydroxyurea in rabbits.
Topics: Animals; Embryo, Mammalian; Female; Free Radical Scavengers; Hydroxyurea; Mannitol; Pregnancy; Rabbi | 1994 |
[Essential thrombocythemia and pregnancy].
Topics: Aspirin; Female; Humans; Hydroxyurea; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Out | 1994 |
Chemotherapy combined with surgery in the treatment of gestational trophoblastic disease (GTD).
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chorioca | 1993 |
Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy.
Topics: Adult; Drug Administration Schedule; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BC | 1993 |
Case studies in binary dispersion.
Topics: Animals; Diet; Embryonic and Fetal Development; Female; Hydroxyurea; Lactation; Mathematics; Models, | 1993 |
[Successful delivery following continuous cytostatic therapy of a leukemic pregnant women].
Topics: Adult; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Hydroxyurea; Infant, | 1993 |
The combination of hydroxyurea and leucapheresis in the treatment of chronic myeloid leukaemia in pregnancy.
Topics: Adult; Combined Modality Therapy; Female; Humans; Hydroxyurea; Immunologic Factors; Incidence; Infan | 1993 |
Alpha-interferon and pregnancy in a patient with CML.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clomiphene; Female; Fertility Agent | 1996 |
[Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Combined Modality Therapy; Drug Administration S | 1996 |
[Essential thrombocythemia in pregnancy. A case report and general considerations].
Topics: Adult; Aspirin; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Infant, Newborn; Male; Plate | 1997 |
Mathematical analysis for teratogenic sensitivity.
Topics: Abnormalities, Drug-Induced; Animals; Computer Simulation; Dose-Response Relationship, Drug; Embryon | 1997 |
Platelet transfusion for surgery in the presence of polycythemia vera.
Topics: Aged; Female; Gastrectomy; Hemostasis; Humans; Hydroxyurea; Platelet Transfusion; Polycythemia Vera; | 1998 |
Confocal laser scanning microscopy of apoptosis in organogenesis-stage mouse embryos.
Topics: Animals; Apoptosis; Coloring Agents; Embryo, Mammalian; Embryonic and Fetal Development; Female; Hyd | 1998 |
Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years.
Topics: Adult; Antineoplastic Agents; Choriocarcinoma; Dactinomycin; Etoposide; Female; Follow-Up Studies; H | 1998 |
Drugs for asthma.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adr | 1999 |
Combined prenatal toxicity of 6-mercaptopurine riboside and hydroxyurea in mice.
Topics: Abnormalities, Drug-Induced; Animals; DNA; Dose-Response Relationship, Drug; Female; Hydroxyurea; Li | 1999 |
Apoptosis and morphology in mouse embryos by confocal laser scanning microscopy.
Topics: Aldehydes; Animals; Apoptosis; Female; Fetus; Fluorescent Dyes; Head; Hydroxyurea; Lysosomes; Mice; | 1999 |
Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cohort Studies | 1999 |
Hydroxyurea in two pregnant women with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents; Female; Humans; Hydroxyurea; Pregnancy; Pregnancy | 1999 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, | 2000 |
Drugs for asthma.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta | 2000 |
An accelerrated-phase CML patient with e19a2 junction of BCR/ABL gene - the first case of transplanted CML with micro bcr.
Topics: Abortion, Therapeutic; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Diseas | 2000 |
The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI).
Topics: Abnormalities, Drug-Induced; Acetates; Administration, Inhalation; Administration, Intranasal; Admin | 2000 |
Hydroxyurea treatment for chronic myeloid leukemia during pregnancy.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Infant, Newborn; Leukemia, Myelogenous, C | 2000 |
Antivirals update.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, C | 1998 |
Exposure to hydroxyurea during pregnancy: a case series.
Topics: Female; Humans; Hydroxyurea; Maternal Exposure; Maternal-Fetal Exchange; Myeloproliferative Disorder | 2001 |
Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL P | 2002 |
Four pregnancies in two patients with essential thrombocythaemia--a case report.
Topics: Adult; Aspirin; Combined Modality Therapy; Cyclooxygenase Inhibitors; Female; Fetal Death; Humans; H | 2002 |
In vivo DNA repair after N-methyl-N-nitrosourea administration to rats of different ages.
Topics: Age Factors; Animals; Brain; Chromatin; DNA; DNA Repair; Female; Fetus; Hydroxyurea; Kidney; Liver; | 1978 |
Stimulation of human chorionic gonadotropin by JAr line choriocarcinoma after inhibition of DNA synthesis.
Topics: Cell Line; Choriocarcinoma; Chorionic Gonadotropin; Cycloheximide; Cytarabine; DNA, Neoplasm; Dose-R | 1979 |
A new combination chemotherapy for resistant trophoblastic disease.
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Resistance; Drug Therapy, Combina | 1979 |
Colony-stimulating factor (CSF) in oestrogen-stimulated spayed murine uteri.
Topics: Animals; Colony-Stimulating Factors; DNA; Estradiol; Female; Glycoproteins; Hydroxyurea; Mice; Mice, | 1977 |
Evidence for Leydig cell dysfunction in rats with seminiferous tubule damage.
Topics: Animals; Chorionic Gonadotropin; Female; Hydroxyurea; Leydig Cells; Luteinizing Hormone; Male; Pregn | 1979 |
Cell death and free radicals: a mechanism for hydroxyurea teratogenesis.
Topics: Animals; Cell Survival; Depression, Chemical; DNA Replication; Female; Free Radicals; Hydroxyurea; K | 1979 |
A teratogenicity study on hydroxyurea and diphenylhydantoin in cats.
Topics: Abnormalities, Drug-Induced; Animals; Cats; Dose-Response Relationship, Drug; Drug Evaluation, Precl | 1979 |
Effects of hydroxyurea during final neuronal DNA synthesis in dorsal root ganglia of rats.
Topics: Abnormalities, Drug-Induced; Animals; Cell Cycle; Cell Division; DNA; Dose-Response Relationship, Dr | 1979 |
DNA repair in normal and preneoplastic mammary tissues.
Topics: Animals; Bromodeoxyuridine; DNA Repair; DNA Replication; DNA, Neoplasm; Female; Hydroxyurea; In Vitr | 1978 |
A comparison of behavioral and anatomical measures of hydroxyurea induced abnormalities.
Topics: Abnormalities, Drug-Induced; Animals; Behavior, Animal; Birth Weight; Brain; Dose-Response Relations | 1978 |
Drug-induced limb dysplasias in fetal rabbits.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Acetazolamide; Animals; Ectoderm; Extremities; | 1977 |
The synthesis of a labile triosephosphate isomerase isozyme in human lymphoblasts and fibroblasts.
Topics: Carbohydrate Epimerases; Dactinomycin; DNA; Female; Fibroblasts; Guanidines; Humans; Hydroxyurea; Is | 1977 |
Effect of differing degrees of destruction of the rat seminiferous epithelium on levels of serum follicle stimulating hormone and androgen binding protein.
Topics: Androgens; Animals; Carrier Proteins; Epididymis; Female; Fetus; Follicle Stimulating Hormone; Hydro | 1977 |
Erythroid colony formation (CFUe) in fetal liver and adult bone marrow and spleen from the mouse.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Cattle; Cell Division; Dose-Response Relationship, Drug; Er | 1976 |
Postnatal effects of chemically induced intrauterine growth retardation on some hematological values in the rat.
Topics: Animals; Diphosphoglyceric Acids; Erythrocyte Count; Erythrocytes; Female; Fetus; Growth; Hematocrit | 1976 |
Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys.
Topics: Amniotic Fluid; Animals; Body Weight; Chorion; Embryo, Mammalian; Female; Gestational Age; Half-Life | 1975 |
Inhibition of RNA synthesis, a possible mode of the embryotoxic action of hydroxyurea.
Topics: Abnormalities, Drug-Induced; Animals; DNA; Dose-Response Relationship, Drug; Embryo, Mammalian; Fema | 1975 |
Maze learning by adult rats after inhibition of neuronal multiplication in utero.
Topics: Animals; Body Weight; Brain; Cell Count; Female; Humans; Hydroxyurea; Learning; Learning Disabilitie | 1975 |
Differential permeability of murine visceral yolk sac to thymidine and to hydroxyurea.
Topics: Animals; Biological Transport; Cell Nucleus; Female; Gestational Age; Hydroxyurea; Mice; Permeabilit | 1975 |
Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia.
Topics: Adult; Female; Humans; Hydroxyurea; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Posit | 1992 |
Hydroxyurea and pregnancy.
Topics: Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Pregnancy | 1992 |
Effects of acid and basic fibroblast growth factor and heparin on resorption of cultured fetal rat long bones.
Topics: Animals; Aphidicolin; Bone and Bones; Bone Resorption; Culture Techniques; Female; Fibroblast Growth | 1991 |
The nature of the embryo-protective interaction of propyl gallate with hydroxyurea.
Topics: Abnormalities, Drug-Induced; Animals; DNA; Embryo, Mammalian; Female; Hydroxyurea; Injections; Necro | 1990 |
Ethoxyquin and nordihydroguaiaretic acid reduce hydroxyurea developmental toxicity.
Topics: Abnormalities, Drug-Induced; Animals; Antioxidants; Body Weight; Embryo, Mammalian; Ethoxyquin; Fema | 1990 |
EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Doxorubicin; | 1988 |
Modified Bagshawe's regimen in high-risk gestational trophoblastic disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1986 |
Effects of DNA and prostaglandin synthesis inhibitors on the stimulation of bone resorption by epidermal growth factor in fetal rat long-bone cultures.
Topics: Animals; Aphidicolin; Bone Resorption; Diterpenes; DNA Replication; Epidermal Growth Factor; Female; | 1986 |
A cytotoxic DNA precursor is taken up selectively by human cancer xenografts.
Topics: Animals; Choriocarcinoma; Colon; DNA; Female; Fluorouracil; Humans; Hydroxyurea; Idoxuridine; Methot | 1987 |
In utero morphological effects of hydroxyurea on the fetal development in Sprague-Dawley rats.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Embryonic and Fetal Development; Female; Fetal De | 1987 |
Teratologic and postnatal evaluation of aniline hydrochloride in the Fischer 344 rat.
Topics: Abnormalities, Drug-Induced; Aniline Compounds; Animals; Animals, Newborn; Blood; Body Weight; Eryth | 1985 |
Teratologic evaluation of dinitrotoluene in the Fischer 344 rat.
Topics: Animals; Blood Cell Count; Dinitrobenzenes; Female; Fetus; Gestational Age; Hydroxyurea; Male; Nitro | 1985 |
The teratogenic interaction of hydroxyurea and 5-bromodeoxyuridine examined with the aid of limb culture and image analysis.
Topics: Abnormalities, Drug-Induced; Animals; Bone and Bones; Bromodeoxyuridine; Culture Techniques; Drug In | 1985 |
DNA synthesis inhibition, cytotoxicity and their relationship to teratogenesis following administration of a nicotinamide antagonist, aminothiadiazole, to pregnant rats.
Topics: Abnormalities, Drug-Induced; Animals; Cleft Palate; Cytarabine; Depression, Chemical; DNA; Female; F | 1973 |
[Studies on the teratogenic effect of hydroxyurea during the early and embryonic development of mice].
Topics: Abnormalities, Drug-Induced; Animals; Cleft Palate; Embryo, Mammalian; Encephalocele; Female; Fetal | 1969 |
[Letter: Teratogenic effects of medications].
Topics: Abnormalities, Drug-Induced; Adult; Chlorambucil; Female; Humans; Hydroxyurea; Leukemia, Lymphoid; M | 1974 |
Pharmacodynamic principles in chemical teratology: dose-effect relationships.
Topics: Abnormalities, Drug-Induced; Adsorption; Cyclophosphamide; Dose-Response Relationship, Drug; Drug-Re | 1972 |
Protective effect of deoxycytidylic acid (CdMP) on hydroxyurea-induced malformations in rats.
Topics: Abnormalities, Drug-Induced; Animals; Cytosine Nucleotides; Female; Fetus; Hydroxyurea; Pregnancy; R | 1973 |
Postnatal effects in rats of prenatal treatment with hydroxyurea.
Topics: Abnormalities, Drug-Induced; Analysis of Variance; Animals; Behavior, Animal; Body Weight; Embryo, M | 1973 |
Relationship of temporal patterns of cell death and development to malformations in the rat limb. Possible mechanisms of teratogenesis with inhibitors of DNA synthesis.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Animals; Cell Survival; Cytarabine; DNA; Ectod | 1973 |
Androgen-induced sexual differentiation of the brain is blocked by inhibitors of DNA and RNA synthesis.
Topics: Animals; Animals, Newborn; Brain; Dactinomycin; Depression, Chemical; DNA; Estrus; Female; Fluoroura | 1974 |
Stimulation of DNA synthesis by prolactin in rabbit mammary tissue.
Topics: Animals; Autoradiography; Chromatography; Culture Techniques; DNA; Female; Hydroxyurea; Lactation; M | 1974 |
Synchronisation in vivo: temporary inhibition of DNA synthesis in the rat embryo with hydroxyurea.
Topics: Animals; Body Weight; DNA; Female; Fetus; Gestational Age; Half-Life; Hydroxyurea; Injections, Intra | 1971 |
[The role of cytokinetically resting cells for the regeneration of an aplastic bone marrow. Autoradiographic studies on rat].
Topics: Animals; Animals, Newborn; Autoradiography; Bone Marrow; Bone Marrow Cells; Epithelium; Female; Hema | 1971 |
Regulation of glucose 6-phosphate dehydrogenase formation in mammary organ culture.
Topics: Amino Acids; Animals; Colchicine; Culture Media; Cysteine; Dactinomycin; DNA; Female; Fructose; Gluc | 1971 |
DNA synthesis inhibition and cell death associated with hydroxyurea teratogenesis in rat embryos.
Topics: Abnormalities, Drug-Induced; Animals; Cell Division; Central Nervous System; DNA; Embryo, Mammalian; | 1971 |
[Effect of cytostatics on the facial development of rats].
Topics: Abnormalities, Drug-Induced; Abnormalities, Severe Teratoid; Animals; Antineoplastic Agents; Cycloph | 1969 |
Biochemical changes during development of mouse mammary tissue in organ culture.
Topics: Animals; Carbon Isotopes; Caseins; Colchicine; Corticosterone; Culture Techniques; Cycloheximide; Da | 1970 |
Teratological studies of p-butoxyphenylacethydroxamic acid (CP 1044 J3) in rats and rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Embryo, Mammalian; Female; Fetal Death; Hydroxamic Acids; Hydr | 1970 |
Production of experimental models of foetal growth retardation by inhibition of DNA or protein synthesis.
Topics: Analysis of Variance; Animals; Body Weight; Brain; Cycloheximide; DNA; Embryonic and Fetal Developme | 1970 |
The role of slowly proliferating cells in rat bone marrow during regeneration following hydroxyurea.
Topics: Animals; Autoradiography; Bone Marrow; Bone Marrow Cells; Cell Count; Cell Division; Female; Hematop | 1970 |
[Chemical constitution and teratogenic effect in rats. I. Carbonic acid amides, carbonic acid hydrazides and hydroxamic acids].
Topics: Abnormalities, Drug-Induced; Amides; Animals; Brain; Embryo, Mammalian; Embryonic and Fetal Developm | 1968 |
Increase in activity of glucose 6-phosphate dehydrogenase in mouse mammary tissue cultured in insulin.
Topics: Adipose Tissue; Animals; Corticosterone; Culture Techniques; Cycloheximide; Dactinomycin; DNA; Femal | 1969 |